Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aldeyra Therapeutics ( (ALDX) ) has provided an update.
On July 17, 2025, Aldeyra Therapeutics announced that the FDA has accepted the resubmitted New Drug Application for reproxalap, an investigational drug for dry eye disease, with a target action date set for December 16, 2025. This acceptance follows a clinical trial demonstrating reproxalap’s efficacy in reducing ocular discomfort, potentially positioning it as a unique treatment option for dry eye disease, impacting Aldeyra’s market presence and offering new possibilities for stakeholders.
The most recent analyst rating on (ALDX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aldeyra Therapeutics stock, see the ALDX Stock Forecast page.
Spark’s Take on ALDX Stock
According to Spark, TipRanks’ AI Analyst, ALDX is a Underperform.
Aldeyra Therapeutics faces substantial financial and regulatory challenges, reflected in its low overall score. The lack of revenue and continuous losses are significant risks, compounded by negative technical indicators. The recent FDA response letter adds further uncertainty. However, strong cash reserves and a strategic board appointment provide some potential for recovery if product development succeeds.
To see Spark’s full report on ALDX stock, click here.
More about Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company focused on developing innovative therapies for immune-mediated and metabolic diseases. The company aims to modulate protein systems to optimize multiple pathways while minimizing toxicity. Its product candidates include RASP modulators for systemic and retinal diseases, with late-stage candidates like reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191 for vitreoretinal lymphoma and retinitis pigmentosa.
Average Trading Volume: 1,107,434
Technical Sentiment Signal: Buy
Current Market Cap: $297.7M
For an in-depth examination of ALDX stock, go to TipRanks’ Overview page.